Lessons from the aprotinin saga: Current perspective on antifibrinolytic therapy in cardiac surgery

Journal of Anesthesia

Volumn 24, Issue 1, 2010, Pages 96-106

  Ide, Masahiro ^a   Bolliger, Daniel ^b   Taketomi, Taro ^b   Tanaka, Kenichi A ^b  

^a Anesthesia Associates of KOBE   (Japan)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aminocaproic acid; Antifibrinolytic therapy; Aprotinin; Complications; Tranexamic acid

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; ALPHA 2 ANTIPLASMIN; AMINOCAPROIC ACID; APROTININ; BERIPLEX; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 13 CONCENTRATE; CLOPIDOGREL; COMPLEMENT COMPONENT C1S INHIBITOR; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; LYSINE DERIVATIVE; OCTAPLEX; PLACEBO; PLASMINOGEN; PREKALLIKREIN; RECOMBINANT BLOOD CLOTTING FACTOR 13; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIASTAP; SERINE PROTEINASE; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

CARDIOPULMONARY BYPASS; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; ENZYME ACTIVATION; FIBRINOLYSIS; HEMOPHILIA; HUMAN; NONHUMAN; OFF LABEL DRUG USE; POSTOPERATIVE HEMORRHAGE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SEIZURE; THROMBOSIS; VIRUS INACTIVATION;

6-AMINOCAPROIC ACID; ANIMALS; ANTIFIBRINOLYTIC AGENTS; APROTININ; CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; HUMANS; THROMBOSIS; TRANEXAMIC ACID;

EID: 76649145106     PISSN: 09138668     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00540-009-0866-9     Document Type: Review

References (107)

1. LJ Dacey JJ Munoz YR Baribeau ER Johnson S Lahey BJ Leavitt RD Quinn WC Nugent JD Birkmeyer GT O'Connor 1998 Reexploration for hemorrhage following coronary artery bypass grafting: incidence and risk factors Arch Surg 133 442 447 9565127
2. CG Koch L Li AI Duncan T Mihaljevic FD Loop NJ Starr EH Blackstone 2006 Transfusion in coronary artery bypass grafting is associated with reduced long-term survival Ann Thorac Surg 81 1650 1657 16631651
3. CG Koch L Li DI Sessler P Figueroa GA Hoeltge T Mihaljevic EH Blackstone 2008 Duration of red-cell storage and complications after cardiac surgery N Engl J Med 358 1229 1239 18354101
4. GJ Despotis G Gravlee K Filos J Levy 1999 Anticoagulation monitoring during cardiac surgery: a review of current and emerging techniques Anesthesiology 91 1122 1151 10519514
5. PM Mannucci M Levi 2007 Prevention and treatment of major blood loss N Engl J Med 356 2301 2311 17538089
6. Okamoto S. Strategies for creating new medicines. Kobe: Kobe Research Project on Thrombosis and Hemostasis; 2003.
7. DA Fergusson PC Hebert CD Mazer S Fremes C MacAdams JM Murkin K Teoh PC Duke R Arellano MA Blajchman JS Bussieres D Cote J Karski R Martineau JA Robblee M Rodger G Wells J Clinch R Pretorius B Investigators 2008 A comparison of aprotinin and lysine analogues in high-risk cardiac surgery N Engl J Med 358 2319 2331 18480196
8. JM Stassen AM Lambeir G Matthyssens WC Ripka A Nystrom JJ Sixma J Vermylen 1995 Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties Thromb Haemost 74 646 654 8585001
9. D Royston R Cardigan C Gippner-Steppert M Jochum 2001 Is perioperative plasma aprotinin concentration more predictable and constant after a weight-related dose regimen? Anesth Analg 92 830 836 11273910
10. E Bennett-Guerrero JG Sorohan AT Canada L Ayuso MF Newman JG Reves MG Mythen 1997 Epsilon-aminocaproic acid plasma levels during cardiopulmonary bypass Anesth Analg 85 248 251 9249095
11. NP Dowd JM Karski DC Cheng JA Carroll Y Lin RL James J Butterworth 2002 Pharmacokinetics of tranexamic acid during cardiopulmonary bypass Anesthesiology 97 390 399 12151929
12. DT Mangano IC Tudor C Dietzel Multicenter Study of Perioperative Ischemia Research G, Ischemia Research, Education F 2006 The risk associated with aprotinin in cardiac surgery N Engl J Med 354 353 365 16436767
13. DT Mangano Y Miao A Vuylsteke IC Tudor R Juneja D Filipescu A Hoeft ML Fontes Z Hillel E Ott T Titov C Dietzel J Levin Investigators of The Multicenter Study of Perioperative Ischemia Research G, Ischemia Research, Education F 2007 Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery JAMA 297 471 479 17284697
14. N Aoki Y Sakata A Ichinose 1983 Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency Blood 62 1118 1122 6626743
15. A Ichinose N Aoki 1986 The initiation of fibrinolysis in alpha 2-plasmin inhibitor deficient plasma. Role of fibrin Thromb Res 41 847 854 2939589
16. NA Booth AJ Simpson A Croll B Bennett IR MacGregor 1988 Plasminogen activator inhibitor (PAI-1) in plasma and platelets Br J Haematol 70 327 333 3264718
17. LA Robbie NA Booth AM Croll B Bennett 1993 The roles of alpha 2-antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis Thromb Haemost 70 301 306 8236139
18. Y Sakata N Aoki 1980 Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor J Clin Invest 65 290 297 6444305
19. N Aoki H Saito T Kamiya K Koie Y Sakata M Kobakura 1979 Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency J Clin Invest 63 877 884 156196
20. L Bajzar J Morser M Nesheim 1996 TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex J Biol Chem 271 16603 16608 8663147
21. J Felez CJ Chanquia P Fabregas EF Plow LA Miles 1993 Competition between plasminogen and tissue plasminogen activator for cellular binding sites Blood 82 2433 2441 8400293
22. M Schneider M Boffa R Stewart M Rahman M Koschinsky M Nesheim 2002 Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme J Biol Chem 277 1021 1030 11684677
23. DV Sakharov JF Nagelkerke DC Rijken 1996 Rearrangements of the fibrin network and spatial distribution of fibrinolytic components during plasma clot lysis J Biol Chem 271 2133 2138 8567670
24. EG Levin U Marzec J Anderson LA Harker 1984 Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells J Clin Invest 74 1988 1995 6542570
25. WL Chandler WC Levy RC Veith JR Stratton 1993 A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training Blood 81 3293 3302 8507867
26. U Wall S Jern L Tengborn C Jern 1998 Evidence of a local mechanism for desmopressin-induced tissue-type plasminogen activator release in human forearm Blood 91 529 537 9427706
27. JJ Emeis 1992 Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products Ann NY Acad Sci 667 249 258 1309043
28. K Tanaka T Morimoto I Yada M Kusagawa K Deguchi 1987 Physiologic role of enhanced fibrinolytic activity during cardiopulmonary bypass in open heart surgery ASAIO Trans 33 505 509 3499923
29. D Journois P Mauriat P Pouard P Marchot J Amiral D Safran 1994 Assessment of coagulation factor activation during cardiopulmonary bypass with a new monoclonal antibody J Cardiothorac Vasc Anesth 8 157 161 8204808
30. H-M Kang MH Kalnoski M Frederick WL Chandler 2005 The kinetics of plasmin inhibition by aprotinin in vivo Thromb Res 115 327 340 15668193
31. LA Harker TW Malpass HE Branson EA Hessel 2nd SJ Slichter 1980 Mechanism of abnormal bleeding in patients undergoing cardiopulmonary bypass: acquired transient platelet dysfunction associated with selective alpha-granule release Blood 56 824 834 6448643
32. M Weinstein J Ware J Troll E Salzman 1988 Changes in von Willebrand factor during cardiac surgery: effect of desmopressin acetate Blood 71 1648 1655 3259441
33. MG Rondaij R Bierings A Kragt JA van Mourik J Voorberg 2006 Dynamics and plasticity of Weibel-Palade bodies in endothelial cells Arterioscler Thromb Vasc Biol 26 1002 1007 16469951
34. RP Tracy DZ Rubin KG Mann EG Bovill M Rand D Geffken PB Tracy 1997 Thrombolytic therapy and proteolysis of factor V J Am Coll Cardiol 30 716 724 9283531
35. K Nogami M Shima T Matsumoto K Nishiya I Tanaka A Yoshioka 2007 Mechanisms of plasmin-catalyzed inactivation of factor VIII: a crucial role for proteolytic cleavage at Arg336 responsible for plasmin-catalyzed factor VIII inactivation J Biol Chem 282 5287 5295 17189254
36. EM Cramer H Lu JP Caen C Soria MC Berndt D Tenza 1991 Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation Blood 77 694 699 1825180
37. TM Quinton S Kim CK Derian J Jin SP Kunapuli 2004 Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4 J Biol Chem 279 18434 18439 14973136
38. BP Bidstrup D Royston RN Sapsford KM Taylor 1989 Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol) J Thorac Cardiovasc Surg 97 364 372 2465457
39. JC Horrow J Hlavacek MD Strong W Collier I Brodsky SM Goldman IP Goel 1990 Prophylactic tranexamic acid decreases bleeding after cardiac operations J Thorac Cardiovasc Surg 99 70 74 2403616
40. A Kuitunen S Hiippala E Vahtera V Rasi M Salmenpera 2005 The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery Acta Anaesthesiol Scand 49 1272 1279 16146463
41. M Levi ME Cromheecke E de Jonge MH Prins BJ de Mol E Briet HR Buller 1999 Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints Lancet 354 1940 1947 10622296
42. A Sedrakyan T Treasure JA Elefteriades 2004 Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials J Thorac Cardiovasc Surg 128 442 448 15354106
43. J van der Linden G Lindvall U Sartipy 2005 Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial Circulation 112 I276 I280 16159831
44. GJ Despotis JH Joist CW Hogue A Alsoufiev D Joiner-Maier SA Santoro E Spitznagel JI Weitz LT Goodnough 1996 More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT Thromb Haemost 76 902 908 8972009
45. JH Levy GJ Despotis F Szlam P Olson D Meeker A Weisinger 2002 Recombinant human transgenic antithrombin in cardiac surgery: a dose-finding study Anesthesiology 96 1095 1102 11981148
46. J Langdown DJD Johnson TP Baglin JA Huntington 2004 Allosteric activation of antithrombin critically depends upon hinge region extension J Biol Chem 279 47288 47297 15326167
47. W Dietrich M Spannagl W Schramm W Vogt A Barankay JA Richter 1991 The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass J Thorac Cardiovasc Surg 102 505 514 1833592
48. MH Staples RF Dunton KJ Karlson HK Leonardi RL Berger 1994 Heparin resistance after preoperative heparin therapy or intraaortic balloon pumping Ann Thorac Surg 57 1211 1216 8179387
49. TE Warkentin 1996 Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/ anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia Transfus Med Rev 10 249 258 8899954
50. W Korte K Gabi M Rohner A Gahler C Szadkowski TW Schnider J Lange W Riesen 2005 Preoperative fibrin monomer measurement allows risk stratification for high intraoperative blood loss in elective surgery Thromb Haemost 94 211 215 16113806
51. S Suzuki T Matsuo H Kobayashi M Matsuo C Shimamo M Koide S Sakamoto 2000 Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters Thromb Res 98 269 279 10822073
52. MC Minnema H ten Cate EJ van Beek A van den Ende CE Hack DP Brandjes 1997 Effects of heparin therapy on fibrinolysis in patients with pulmonary embolism Thromb Haemost 77 1164 1167 9241751
53. Nieuwenhuizen W, Bos R. Soluble fibrin and degradation products of fibrinogen (FgDP), fibrin (FbDP; D-dimer) and total of FgDP and FbDP (TDP). In: Jespersen J, Bertina RM, Haverkate F, editors. Laboratory techniques in thrombosis - a manual. 2/e ed. Dordrecht: Kluwer Academic Publishers; 2000. p. 275-84.
54. L Ferrucci A Corsi F Lauretani S Bandinelli B Bartali DD Taub JM Guralnik DL Longo 2005 The origins of age-related proinflammatory state Blood 105 2294 2299 15572589
55. D Royston 1994 Intraoperative coronary thrombosis: can aprotinin be incriminated? J Cardiothorac Vasc Anesth 8 137 141 7515702
56. EL Alderman JH Levy JB Rich M Nili B Vidne H Schaff G Uretzky G Pettersson JJ Thiis CB Hantler B Chaitman A Nadel 1998 Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial J Thorac Cardiovasc Surg 116 716 730 9806378
57. DT Mangano Multicenter Study of Perioperative Ischemia Research G 2002 Aspirin and mortality from coronary bypass surgery N Engl J Med 347 1309 1317 12397188
58. S Aronson ML Fontes Y Miao DT Mangano Investigators of the Multicenter Study of Perioperative Ischemia Research G, Ischemia Research, Education F 2007 Risk index for perioperative renal dysfunction/failure: critical dependence on pulse pressure hypertension Circulation 115 733 742 17283267
59. K Yamamoto DJ Loskutoff 1996 Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator J Clin Invest 97 2440 2451 8647936 (Pubitemid 26187331)
60. RD Rosenberg 2001 Vascular-bed-specific hemostasis and hypercoagulable states: clinical utility of activation peptide assays in predicting thrombotic events in different clinical populations Thromb Haemost 86 41 50 11487031
61. P Carmeliet L Schoonjans L Kieckens B Ream J Degen R Bronson R De Vos JJ van den Oord D Collen RC Mulligan 1994 Physiological consequences of loss of plasminogen activator gene function in mice Nature 368 419 424 8133887
62. C Krishnamurti C Bolan CA Colleton TM Reilly BM Alving 1993 Role of plasminogen activator inhibitor-1 in promoting fibrin deposition in rabbits infused with ancrod or thrombin Blood 82 3631 3636 8260701
63. DA Lane H Philippou JA Huntington 2005 Directing thrombin Blood 106 2605 2612 15994286
64. G Muller-Berghaus L Roka HG Lasch 1973 Induction of glomerular microclot formation by fibrin monomer infusion Thromb Diath Haemorrh 29 375 383 4543443
65. WC Aird 2007 Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms Circ Res 100 158 173 17272818
66. WC Aird 2007 Phenotypic heterogeneity of the endothelium: II. Representative vascular beds Circ Res 100 174 190 17272819
67. AR Giles ME Nesheim SW Herring H Hoogendoorn DC Stump CM Heldebrant 1990 The fibrinolytic potential of the normal primate following the generation of thrombin in vivo Thromb Haemost 63 476 481 2402750
68. FB Taylor Jr H Hoogendoorn AC Chang G Peer ME Nesheim R Catlett DC Stump AR Giles 1992 Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein C Blood 79 1720 1728 1558968
69. SR Hanson JH Griffin LA Harker AB Kelly CT Esmon A Gruber 1993 Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates J Clin Invest 92 2003 2012 8408654
70. CT Esmon 2003 The protein C pathway Chest 124 26S 32S 12970121
71. Y Sakata S Curriden D Lawrence JH Griffin DJ Loskutoff 1985 Activated protein C stimulates the fibrinolytic activity of cultured endothelial cells and decreases antiactivator activity Proc Natl Acad Sci USA 82 1121 1125 3871946
72. GAF Nicolaes B Dahlback 2002 Factor V and thrombotic disease: description of a Janus-faced protein Arterioscler Thromb Vasc Biol 22 530 538 11950687
73. R Sniecinski F Szlam EP Chen SO Bader JH Levy KA Tanaka 2008 Antithrombin deficiency increases thrombin activity after prolonged cardiopulmonary bypass Anesth Analg 106 713 718 18292407
74. RE Jordan RM Nelson J Kilpatrick JO Newgren PC Esmon MA Fournel 1989 Inactivation of human antithrombin by neutrophil elastase. Kinetics of the heparin-dependent reaction J Biol Chem 264 10493 10500 2732232
75. TA Drake W Ruf JH Morrissey TS Edgington 1989 Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line J Cell Biol 109 389 395 2663880
76. KL Moore CT Esmon NL Esmon 1989 Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture Blood 73 159 165 2535943
77. S Gando T Kameue S Nanzaki Y Nakanishi 1995 Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome Thromb Res 80 519 526 8610280
78. KA Tanaka R Sniecinski 2006 Systemic thromboses after cardiopulmonary bypass: is it thrombin or antithrombin? Anesthesiology 105 428 16871082
79. KE Brummel SG Paradis S Butenas KG Mann 2002 Thrombin functions during tissue factor-induced blood coagulation Blood 100 148 152 12070020
80. AL Kuharsky AL Fogelson 2001 Surface-mediated control of blood coagulation: the role of binding site densities and platelet deposition Biophys J 80 1050 1074 11222273
81. L Shore-Lesserson DL Reich 2006 A case of severe diffuse venous thromboembolism associated with aprotinin and hypothermic circulatory arrest in a cardiac surgical patient with factor V Leiden Anesthesiology 105 219 221 16810016
82. AD Lichtman V Carullo M Minhaj K Karkouti 2007 Case 6-2007: massive intraoperative thrombosis and death after recombinant activated factor VII administration J Cardiothorac Vasc Anesth 21 897 902 18068077
83. CH Dusel C Grundmann S Eich R Seitz H Konig 2004 Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates Blood Coagul Fibrinolysis 15 405 411 15205589
84. F Szlam T Taketomi CA Sheppard CL Kempton JH Levy KA Tanaka 2008 Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma Anesth Analg 106 719 724 18292408
85. RM Sniecinski EP Chen KA Tanaka 2008 Reduced levels of fibrin (antithrombin I) and antithrombin III underlie coagulopathy following complex cardiac surgery Blood Coagul Fibrinolysis 19 178 179 18277140
86. JH Levy NF Adkinson Jr 2008 Anaphylaxis during cardiac surgery: implications for clinicians Anesth Analg 106 392 403 18227290
87. OD Ratnoff 1969 Epsilon aminocaproic acid - a dangerous weapon N Engl J Med 280 1124 1125 5813521
88. C Charytan D Purtilo 1969 Glomerular capillary thrombosis and acute renal failure after epsilon-amino caproic acid therapy N Engl J Med 280 1102 1104 5778426
89. PS Garcha CVR Mohan RM Sharma 2007 Death after an inadvertent intrathecal injection of tranexamic acid Anesth Analg 104 241 242 17179315
90. K Martin G Wiesner T Breuer R Lange P Tassani 2008 The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients Anesth Analg 107 1783 1790 19020118
91. R Furtmuller MG Schlag M Berger R Hopf S Huck W Sieghart H Redl 2002 Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a gamma-aminobutyric acid(A) receptor antagonistic effect J Pharmacol Exp Ther 301 168 173 11907171
92. M Levi K Hovingh SC Cannegieter M Vermeulen HR Buller FR Rosendaal 2008 Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based Blood 111 4471 4476 18316627
93. V Casati C Gerli A Franco P Della Valle S Benussi O Alfieri G Torri A D'Angelo 2001 Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques Anesthesiology 95 1103 1109 11684978
94. D Bolliger F Szlam RJ Molinaro N Rahe-Meyer JH Levy KA Tanaka 2009 Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model Br J Anaesth 102 793 799 19420005
95. MT Ganter CK Hofer 2008 Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices Anesth Analg 106 1366 1375 18420846
96. KA Tanaka NS Key JH Levy 2009 Blood coagulation: hemostasis and thrombin regulation Anesth Analg 108 1433 1446 19372317
97. DV Sakharov DC Rijken 1995 Superficial accumulation of plasminogen during plasma clot lysis Circulation 92 1883 1890 7671373
98. M Blome F Isgro AH Kiessling J Skuras H Haubelt P Hellstern W Saggau 2005 Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery Thromb Haemost 93 1101 1107 15968395
99. RC Carroll JJ Chavez CC Snider DS Meyer RA Muenchen 2006 Correlation of perioperative platelet function and coagulation tests with bleeding after cardiopulmonary bypass surgery J Lab Clin Med 147 197 204 16581348
100. JPR Pelletier S Transue EL Snyder 2006 Pathogen inactivation techniques Baillieres Best Pract Res Clin Haematol 19 205 242
101. JH Levy KA Tanaka W Dietrich 2008 Perioperative hemostatic management of patients treated with vitamin K antagonists Anesthesiology 109 905 917
102. P Chowdhury AG Saayman U Paulus GP Findlay PW Collins 2004 Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients Br J Haematol 125 69 73 15015971
103. DJ Triulzi 2009 Transfusion-related acute lung injury: current concepts for the clinician Anesth Analg 108 770 776 19224781
104. P Diprose MJ Herbertson D O'Shaughnessy RS Gill 2005 Activated recombinant factor VII after cardiopulmonary bypass reduces allogeneic transfusion in complex non-coronary cardiac surgery: randomized double-blind placebo-controlled pilot study Br J Anaesth 95 596 602 16183679
105. S Romagnoli S Bevilacqua S Gelsomino S Pradella L Ghilli C Rostagno GF Gensini C Sorbara 2006 Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery Anesth Analg 102 1320 1326 16632803
106. KA O'Connell JJ Wood RP Wise JN Lozier M Miles Braun 2006 Thromboembolic adverse events after use of recombinant human coagulation factor VIIa JAMA 295 293 298 16418464
107. W Dietrich S Nicklisch A Koster M Spannagl H Giersiefen A van de Locht 2009 CU-2010-a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties Anesthesiology 110 123 130 19104179